PAUL BOULWARE: Open Payments
NPI 1609912146 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,927 in 109 payments from 20 companies in 2025. Trend: 2023 $1,939 · 2024 $2,086 · 2025 $1,927
Food & beverage: $1,927
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 10 | $287 |
| ABBVIE INC. | 31 | $267 |
| Braeburn Inc. | 14 | $210 |
| Tris Pharma Inc | 9 | $153 |
| Neurocrine BioSciences, Inc. | 7 | $144 |
| Indivior Inc. | 5 | $141 |
| Otsuka America Pharmaceutical, Inc. | 5 | $102 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $94 |
| Janssen Pharmaceuticals, Inc | 4 | $94 |
| Axsome Therapeutics, Inc. | 3 | $86 |
Products named: VRAYLAR, LYBALVI, BRIXADI, Dyanavel XR, INGREZZA, SUBLOCADE, REXULTI, CAPLYTA.
Industry payments across AZ — which companies pay providers there.
